North America Lysosomal Storage Disorder Drugs Market Trends

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

North America Lysosomal Storage Disorder Drugs Market Size, Share, and Trends Analysis Report Trends

  • Pharmaceutical
  • Published Report
  • Oct 2024
  • North America
  • 350 Pages
  • No of Tables: 90
  • No of Figures: 46

“Biotechnology Advancements for Lysosomal Storage Disorders Treatments”

Advancements in biotechnology have played a pivotal role in transforming the treatment landscape for Lysosomal Storage Disorders (LSDs), providing patients with more effective and tailored treatment options. Enzyme Replacement Therapy (ERT) has revolutionized the treatment of Lysosomal Storage Disorders (LSDs) by directly addressing the enzyme deficiencies that cause these conditions. In LSD patients, the lack of specific enzymes leads to the accumulation of toxic substances in cells, damaging organs and tissues. ERT works by administering synthetic enzymes to compensate for the missing ones, improving metabolic functions and alleviating symptoms. Over the years, ERT has advanced significantly, with new, more effective formulations and delivery methods that improve enzyme absorption and reduce side effects. These innovations have resulted in better clinical outcomes, this trend slowed disease progression, reduced organ damage, and enhanced patient quality of life.

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET

1.4 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 SECONDARY SOURCES

2.1 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PORTER’S FIVE FORCES

4.2 PIPELINE ANALYSIS

5 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: REGULATIONS

5.1 REGULATORY AUTHORITIES IN NORTH AMERICA

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 BIOTECHNOLOGY ADVANCEMENTS FOR LYSOSOMAL STORAGE DISORDERS TREATMENTS

6.1.2 EMERGING PERSONALIZED MEDICINE FOR LYSOSOMAL STORAGE DISORDERS

6.1.3 INCREASED GOVERNMENT FUNDING FOR RESEARCH INTO RARE DISEASE TREATMENTS

6.1.4 COLLABORATIONS AND PARTNERSHIPS BETWEEN PHARMACEUTICAL COMPANIES AND RESEARCH INSTITUTIONS

6.2 RESTRAINTS

6.2.1 LACK OF AWARENESS AMONG HEALTHCARE PROFESSIONALS AND PATIENTS

6.2.2 PROLONGED DRUG APPROVAL PROCEDURES

6.3 OPPORTUNITIES

6.3.1 INCREASING NUMBER OF PIPELINE DRUGS

6.3.2 GROWING EMPHASIS ON EARLY DIAGNOSIS

6.3.3 ADVANCEMENTS IN GENE THERAPY FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS

6.4 CHALLENGES

6.4.1 SIGNIFICANT EXPENSES RELATED TO THE TREATMENT OF THE DISEASE

6.4.2 NARROW PATIENT BASE SUFFERING FROM LYSOSOMAL STORAGE DISORDERS

7 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER

7.1 OVERVIEW

7.2 GAUCHER DISEASE

7.2.1 TYPE 1

7.2.2 TYPE 3

7.2.3 TYPE 2

7.3 FABRY DISEASE

7.4 POMPE DISEASE

7.4.1 INFANTILE-ONSET POMPE

7.4.2 LATE-ONSET POMPE

7.5 MUCOPOLYSACCHARIDOSIS (MPS)

7.5.1 MPS I

7.5.2 MPS II

7.5.3 MPS IV

7.5.4 MPS VI

7.5.5 MPS III

7.6 NIEMANN-PICK DISEASE

7.6.1 TYPE C

7.6.2 TYPE B

7.6.3 TYPE A

7.7 KRABBE DISEASE

7.8 OTHERS

8 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS

8.1 OVERVIEW

8.2 IMIGLUCERASE

8.3 AGALSIDASE BETA

8.4 IDURSULFASE

8.5 ALGLUCOSIDASE ALPHA

8.6 VELAGLUCERASE

8.7 TALIGLUCERASE ALFA

8.8 LARONIDASE

8.9 AGALSIDASE ALPHA

8.1 GALSULFASE

8.11 AVALGLUCOSIDASE ALFA

8.12 OTHERS

9 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE

9.1 OVERVIEW

9.2 ENZYME REPLACEMENT THERAPY (ERT)

9.3 SUBSTRATE REDUCTION THERAPY (SRT)

9.4 CHAPERONE THERAPY

9.5 OTHERS

10 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER

10.1 OVERVIEW

10.2 MALE

10.3 FEMALE

11 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP

11.1 OVERVIEW

11.2 PEDIATRIC

11.3 ADULT

11.4 GERIATRIC

12 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 HOSPITAL PHARMACIES

12.3 DRUGS STORES AND RETAIL PHARMACIES

12.4 ONLINE PHARMACIES

13 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 INTRAVENOUS (IV)

13.3 SUBCUTANEOUS (SC)

13.4 ORAL

13.5 OTHERS

14 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION

14.1 NORTH AMERICA

14.1.1 U.S.

14.1.2 CANADA

14.1.3 MEXICO

15 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

16 SWOT ANALYSIS

17 COMPANY PROFILES

17.1 SANOFI

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENT

17.2 BIOMARIN

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENT

17.3 PFIZER INC.

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENT

17.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENT

17.5 AMICUS THERAPEUTIC, INC.

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENT

17.6 CHIESI FARMACEUTICI S.P.A.

17.6.1 COMPANY SNAPSHOT

17.6.2 PRODUCT PORTFOLIO

17.6.3 RECENT DEVELOPMENT

17.7 DENALI THERAPEUTICS

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 PIPELINE PRODUCT PORTFOLIO

17.7.4 RECENT DEVELOPMENT

17.8 FORGE BIOLOGICS

17.8.1 COMPANY SNAPSHOT

17.8.2 PIPELINE PRODUCT PORTFOLIO

17.8.3 RECENT DEVELOPMENT

17.9 JCR PHARMACEUTICALS CO., LTD.

17.9.1 COMPANY SNAPSHOT

17.9.2 REVENUE ANALYSIS

17.9.3 PINELINE PRODUCT PORTFOLIO

17.9.4 PRODUCT PORTFOLIO

17.9.5 RECENT DEVELOPMENT

17.1 ORCHARD THERAPEUTICS PLC

17.10.1 COMPANY SNAPSHOT

17.10.2 REVENUE ANALYSIS

17.10.3 PRODUCT PORTFOLIO

17.10.4 RECENT DEVELOPMENT

17.11 PROTALIX BIOTHERAPEUTICS

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE ANALYSIS

17.11.3 PIPELINE PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENT

17.12 REGENXBIO INC.

17.12.1 COMPANY SNAPSHOT

17.12.2 REVENUE ANALYSIS

17.12.3 PINELINE PRODUCT PORTFOLIO

17.12.4 RECENT DEVELOPMENT

17.13 SANGAMO THERAPEUTICS

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENT

17.14 SPUR THERAPEUTICS

17.14.1 COMPANY SNAPSHOT

17.14.2 PRODUCT PORTFOLIO

17.14.3 RECENT DEVELOPMENT

17.15 ULTRAGENYX PHARMACEUTICAL INC.

17.15.1 COMPANY SNAPSHOT

17.15.2 REVENUE ANALYSIS

17.15.3 PRODUCT PORTFOLIO

17.15.4 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

List of Table

TABLE 1 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 2 NORTH AMERICA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 3 NORTH AMERICA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 4 NORTH AMERICA FABRY DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 5 NORTH AMERICA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 6 NORTH AMERICA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 7 NORTH AMERICA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 8 NORTH AMERICA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 9 NORTH AMERICA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 10 NORTH AMERICA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 11 NORTH AMERICA KRABBE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 12 NORTH AMERICA OTHERS IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 13 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 14 NORTH AMERICA IMIGLUCERASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 15 NORTH AMERICA AGALSIDASE BETA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 16 NORTH AMERICA IDURSULFASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 17 NORTH AMERICA ALGLUCOSIDASE ALPHA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 18 NORTH AMERICA VELAGLUCERASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 19 NORTH AMERICA TALIGLUCERASE ALFA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 20 NORTH AMERICA LARONIDASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 21 NORTH AMERICA AGALSIDASE ALPHA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 22 NORTH AMERICA GALSULFASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 23 NORTH AMERICA AVALGLUCOSIDASE ALFA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 24 NORTH AMERICA OTHERS IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 25 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 26 NORTH AMERICA ENZYME REPLACEMENT THERAPY (ERT) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 27 NORTH AMERICA SUBSTRATE REDUCTION THERAPY (SRT) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 28 NORTH AMERICA CHAPERONE THERAPY IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 29 NORTH AMERICA OTHERS IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 30 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 31 NORTH AMERICA MALE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 32 NORTH AMERICA FEMALE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 33 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 34 NORTH AMERICA PEDIATRIC IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 35 NORTH AMERICA ADULT IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 36 NORTH AMERICA GERIATRIC IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 37 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 38 NORTH AMERICA HOSPITAL PHARMACIES IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 39 NORTH AMERICA DRUGS STORES AND RETAIL PHARMACIES IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 40 NORTH AMERICA ONLINE PHARMACIES IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 41 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 42 NORTH AMERICA INTRAVENOUS (IV) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 43 NORTH AMERICA SUBCUTANEOUS (SC) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 44 NORTH AMERICA ORAL IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 45 NORTH AMERICA OTHERS IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 46 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 47 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 48 NORTH AMERICA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 49 NORTH AMERICA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 50 NORTH AMERICA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 51 NORTH AMERICA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 52 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 53 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 54 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 55 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 56 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 57 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 58 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 59 U.S. GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 60 U.S. POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 61 U.S. MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 62 U.S. NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 63 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 64 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 65 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 66 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 67 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 68 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 69 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 70 CANADA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 71 CANADA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 72 CANADA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 73 CANADA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 74 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 75 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 76 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 77 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 78 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 79 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 80 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 81 MEXICO GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 82 MEXICO POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 83 MEXICO MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 84 MEXICO NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 85 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 86 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 87 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 88 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 89 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 90 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

List of Figure

FIGURE 1 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: SEGMENTATION

FIGURE 10 EXECUTIVE SUMMARY

FIGURE 11 SEVEN SEGMENTS COMPRISE THE NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER

FIGURE 12 STRATEGIC DECISIONS

FIGURE 13 BIOTECHNOLOGY ADVANCEMENTS FOR LYSOSOMAL STORAGE DISORDER TREATMENTS IS EXPECTED TO DRIVE THE NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET IN THE FORECAST PERIOD

FIGURE 14 GAUCHER DISEASE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET IN 2025 & 2032

FIGURE 15 PESTEL ANALYSIS

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET

FIGURE 17 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE OF DISORDER, 2024

FIGURE 18 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE OF DISORDER, 2025-2032 (USD MILLION)

FIGURE 19 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE OF DISORDER, CAGR (2025-2032)

FIGURE 20 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE OF DISORDER, LIFELINE CURVE

FIGURE 21 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DRUGS, 2024

FIGURE 22 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DRUGS, 2025-2032 (USD MILLION)

FIGURE 23 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DRUGS, CAGR (2025-2032)

FIGURE 24 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DRUGS, LIFELINE CURVE

FIGURE 25 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE, 2024

FIGURE 26 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE, 2025-2032 (USD MILLION)

FIGURE 27 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE, CAGR (2025-2032)

FIGURE 28 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 29 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY GENDER, 2024

FIGURE 30 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY GENDER, 2025-2032 (USD MILLION)

FIGURE 31 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY GENDER, CAGR (2025-2032)

FIGURE 32 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 33 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY AGE GROUP, 2024

FIGURE 34 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY AGE GROUP, 2025-2032 (USD MILLION)

FIGURE 35 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY AGE GROUP, CAGR (2025-2032)

FIGURE 36 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 37 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2024

FIGURE 38 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)

FIGURE 39 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)

FIGURE 40 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 41 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2024

FIGURE 42 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)

FIGURE 43 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025-2032)

FIGURE 44 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 45 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: SNAPSHOT 2024

FIGURE 46 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY SHARE 2024 (%)

Frequently Asked Questions

The market is segmented based on Segmentation, By Type of Disorder (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis (MPS), Niemann-Pick Disease, Krabbe Disease, and Others), Type (Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Chaperone Therapy, and Others), Drugs (Imiglucerase, Agalsidase Beta, Idursulfase, Alglucosidase Alpha, Velaglucerase, Taliglucerase Alfa, Laronidase, Agalsidase Alpha, Galsulfase, Avalglucosidase Alfa, and Others), Route of Administration (Intravenous (IV), Subcutaneous (SC), Oral, and Others), Age Group (Pediatric, Adults, and Geriatric), Gender (Male and Female), Distribution Channel  (Hospital Pharmacies, Drugs Stores and Retail Pharmacies, and Online Pharmacies) - Industry Trends and Forecast to 2032 .
The North America Lysosomal Storage Disorder Drugs Market size was valued at USD 4.23 USD Billion in 2024.
The North America Lysosomal Storage Disorder Drugs Market is projected to grow at a CAGR of 9.7% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada, and Mexico.